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(Correspondence should be addressed to A Försti; Email: a.foersti@dkfz-heidelberg.de)AbstractWestern lifestyle leading to obesity and type 2 diabetes has been associated with increased
risk of colorectal cancer (CRC). Diet and related factors may affect the risk by modifying
plasma insulin levels. Thus, the inter-individual variation in insulin signaling may play a
plausible role in the development of CRC. We hypothesized that functional polymorphisms
in the insulin pathway genes INS, INSR, IGFBPI, insulin receptor substrate 1 (IRS1), and
IRS2 may be associated with CRC. We studied the association of five single nucleotide
polymorphisms (SNPs) with the risk of CRC using a hospital-based case–control design with
712 cases and 748 controls from the Czech Republic. The INSR A-603G promoter SNP,
which is located within a known Sp1-binding site, was associated with the risk of CRC, with
carriers of the G allele having a decreased risk (odds ratios (OR) 0.71, 95% confidence
interval (CI) 0.54–0.93). Carrying the variant allele of the IRS1 Gly972Arg SNP further
decreased the risk among the INSR-603G allele carriers (OR 0.28, 95% CI 0.11–0.70).
SNPs in the INS, IGFBPI, and IRS2 genes did not affect the risk of CRC. In conclusion,
genetic variation in the insulin signaling pathway genes may affect the risk of CRC.Endocrine-Related Cancer (2007) 14 733–740Introduction
Twin studies indicate that hereditary factors contribute
tow35% colorectal cancer (CRC) susceptibility, while
the remaining 65% are due to random and shared
environmental factors (Lichtenstein et al. 2000). High
penetrance mutations in the adenomatous polyposis
coli gene and the mismatch repair gene family
contribute to only a small proportion of the familial
component (de la Chapelle 2004). However, there are
also several low-penetrance variants that contribute to
CRC susceptibility (de la Chapelle 2004). Aging and
lifestyle factors like diet, cigarette smoking, alcohol
consumption, and lack of physical activity, influenceEndocrine-Related Cancer (2007) 14 733–740
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Chapelle 2004). The effect of these lifestyle factors on
the risk of CRC may be mediated through the insulin
(INS) pathway (Giovannucci 2001, Sandhu et al.
2002), thus creating a hypothesis that genetic
variation in the genes along the pathway may affect
the risk of CRC.
There are several pieces of evidence indicating that
insulin is associated with the risk of CRC (Giovannucci
2001, Sandhu et al. 2002). In rats, insulin enhances the
growth of aberrant crypt foci, CRC precursor lesions,
and increases the number and the size of the tumors
(Giovannucci 2001). Several studies have also foundBritain
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a link between insulin, type 2 diabetes, obesity and
body size and the risk of CRC (Schoen et al. 1999,
Giovannucci 2001, Calle & Kaaks 2004, Biddinger &
Kahn 2006). There is also an evidence on the
association between the elevated levels of insulin and
an increased risk of CRC in humans (Schoen et al.
1999, Kaaks et al. 2000).
Insulin may regulate cell growth and apoptosis by
binding to its receptor (INSR) or to the structurally
related insulin-like growth factor-I receptor (IGFIR;
LeRoith & Roberts 2003, Biddinger & Kahn 2006).
However, it is a rather weak mitogen and may promote
colorectal carcinogenesis indirectly by regulating
production of the more potent mitogen, IGFI (Gio-
vannucci 2001, Sandhu et al. 2002). Growth hormone
is the main regulator of IGFI. By up-regulating the
production of growth hormone receptor, insulin
increases the production of IGFI. Insulin also decreases
the levels of two IGF-binding proteins (IGFBPI and
IGFBP2), thus affecting the bioavailability of IGFI.
The insulin receptor substrates (IRSs) and Src
homology 2 domain-containing transforming protein
1 (SHC1) are the key mediators of the INS and IGFI
pathways (LeRoith & Roberts 2003, Biddinger & Kahn
2006). Both IRS1 and SHC1 can bind to growth factor
receptor bound protein 2 (GRB2) to activate the Ras/
MAP kinase pathway that regulates cell proliferation
and differentiation. The IRS proteins 1 and 2 can
additionally bind to the p85 subunit of phosphatidyl-
inositol (PI)-3 kinase and activate the serine kinase
PKB/Akt pathway that regulates apoptosis, glucose
metabolism, and lipid biosynthesis.
So far, prostate cancer is the most intensively
studied cancer with regard to the effect of polymorph-
isms in the INS, IRS1, IRS2, and IGFBPI genes on
cancer susceptibility (Ho et al. 2003, Claeys et al.
2005, Li et al. 2005, Neuhausen et al. 2005, Stephens
et al. 2005, Cheng et al. 2006). Only one study has
focused on IRS1 and IRS2 polymorphisms and the risk
of CRC (Slattery et al. 2004). Additionally, a study
investigating the relationship between genetic vari-
ation in the INS, INSR, IRS1, and IRS2 genes and
advanced colorectal adenoma, a cancer precursor, has
been published (Gunter et al. 2007).
In the INS gene, a variable number of tandem repeats
(VNTR) locus that lies next to the transcription start
site, is believed to have a direct effect on insulin
regulation (Bennett & Todd 1996). Tight linkage
disequilibrium (LD) has been reported between several
single nucleotide polymorphisms (SNPs) and the
VNTR (Bennett & Todd 1996). Several groups have
studied the relationship between prostate cancer and
one of the linked SNPs, C1127INSPstI, with734inconsistent results (Ho et al. 2003, Claeys et al.
2005, Li et al. 2005, Neuhausen et al. 2005).
The 5 0-flanking region of the INSR gene plays an
important role in proper expression of the gene (Foti
et al. 2003). There are many regulatory elements
present in the promoter region, including four clusters
of GC boxes that have been reported to be putative
binding sites for the transcription factor Sp1 (Araki
et al. 1991, Haruta et al. 1995, Foti et al. 2003).
Polymorphisms that are located in this region may
affect the gene expression with subsequent impairment
of insulin signaling and action.
High LD has been reported across the entire IGFBPI
gene (Stephens et al. 2005, Cheng et al. 2006). The
Ile253Met SNP is the only validated non-synonymous
SNP and has been associated with diabetic nephro-
pathy (Stephens et al. 2005).
In the IRS1 and IRS2 genes, polymorphisms that
are located close to the tyrosine phosphorylation
sites may cause a change in the tertiary structure of
these proteins and therefore may show an effect on
p85 and GRB2 binding, resulting in impaired
signaling (Wagner et al. 2004).
Here, we investigated the effect of SNPs in several
insulin pathway-related genes on the risk of CRC. We
selected SNPs in the INS, IGFBPI, INSR, IRS1, and
IRS2 genes based on their suggested effect on the gene
expression or the protein function or because they were
in LD with a putatively functional polymorphism. We
investigated their association with the risk of CRC in a
Czech hospital-based case–control population with 712
cases and 748 controls. We additionally evaluated the
effect of gene–gene interactions on the risk of CRC.Materials and methods
Subjects
The present hospital-based case–control study is based
on incident cases, the recruitment of which started in
September 2004 and ended in February 2006. Blood
samples and anamnestic data were provided by six
oncological and five large gastroenterological depart-
ments all over the Czech Republic. The study cases
consist of patients with positive colonoscopic results
for malignancy, histologically confirmed as colon or
rectal carcinomas. Controls were defined as subjects
undergoing colonoscopy for various gastrointestinal
complaints and sampled at the same time as cases.
Their colonoscopic results were negative for malig-
nancy or idiopathic bowel diseases.
Study subjects provided the information on their
lifestyle habits (smoking, drinking, diet, etc.), bodywww.endocrinology-journals.org
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mass index (BMI), diabetes, tentative occupational
exposure to xenobiotics, and family/personal history of
cancer, with the use of structured questionnaires.
Table 1 shows the selected characteristics of the
study population at the time of diagnosis of the cases
and at the time of sample drawing of the controls
respectively. The information about diabetes was self-
reported.
Blood samples were collected from 712 CRC
patients (mean age 62, range 27–90) and 748
regionally matched controls (mean age 53.5, range
29–91). DNA was isolated from coded blood samples
and stored at K80 8C.
All participants signed an informed written consent
and the design of the study was approved by the Ethical
Committee of the Institute of Experimental Medicine,
Prague, Czech Republic.
SNP selection
We sequenced 23 samples in order to screen the entire
INS and IGFBPI gene regions, the promoter (K2221 to
K1 bp) and the published SNPs (http://www.ncbi.nlm.
nih.gov/, http://snpper.chip.org/) in the coding region
of the INSR gene.
We confirmed high LD in the INS gene and selected
the C1127INSPstI SNP (rs3842752) for further
analysis because it has been previously used as a
surrogate for the functional VNTR polymorphism in
studies of diseases related to insulin resistance,
including cancer (Ho et al. 2003, Claeys et al. 2005,
Li et al. 2005, Neuhausen et al. 2005). In the IGFBPI
gene, the only non-synonymous SNP Ile253Met
(rs4619) was in 100% LD with all the other SNPs
along the entire IGFBPI gene region as previously
shown by Cheng et al. (2006) and therefore, we
selected it for further analysis. In the INSR gene, four
promoter and eight coding region SNPs were
confirmed. The A-603G SNP (rs1864010) lies within
a Sp1-binding site and was therefore selected for ourTable 1 Selected characteristics of the study population
Total study population (n)
Males (n (%))
Females (n (%))
Median age (years; range)a
Median BMI (kg/m2; 5th–95th percentiles)b
Self-reported diabetes (n (%))b
Personal history of other cancers (n (%))b
BMI, body mass index.
aAge data were missing from 27 (3.8%) cases and 1 (0.1%) contro
bThe data were available for 420 cases and 343 controls; data wer
www.endocrinology-journals.orgfurther study (Foti et al. 2003). Since all the INSR-
coding region SNPs caused synonymous exchanges
and the two SNPs in the tyrosine kinase domain had a
low minor allele frequency (MAF), %5%, we did not
analyze them further. The IRS1 Gly972Arg
(rs1801278) and the IRS2 Gly1057Asp (rs18050907)
SNPs were selected for further analysis because of
their putative effect on p85 and GRB2 binding
(Wagner et al. 2004).
DNA sequencing
We used DNA sequencing for the initial SNP
screening, for the analyses of the INSR A-603G and
IRS2 Gly1057Asp SNPs. Additionally, about 10% of
the genotyping results were also confirmed. PCR
amplification was performed with 5 ng genomic
DNA in a 10 ml reaction volume using 1! PCR
buffer, 1.5 mM MgCl2, 0.11 mM dNTP mixture, 0.3 U
Platinum Tag DNA polymerase (Invitrogen) and
0.15 mM each primer (Invitrogen). The primer
sequences and corresponding PCR conditions used
for detecting the SNPs in each gene can be obtained
from the corresponding author. For the INSR promoter
A-603G and the IRS2 Gly1057Asp SNPs 5% DMSO
was added to the reaction mixture. The PCR was
carried out in a GeneAmp 9700 PCR system (Applied
Biosystems, Foster City, CA, USA) in the following
conditions: 2 min denaturation at 94 8C followed by
three cycles of 94 8C for 1 min, the optimum annealing
temperature for the respective fragment (available on
request) for 1 min, 72 8C for 1 min, 32 cycles of 94 8C
for 30 s, the optimum annealing temperature minus
1 8C for 30 s, 72 8C for 30 s, and a final extension at
72 8C for 6 min.
The PCR product was cleaned up using 0.75 ml
ExoSapIT (USB Amersham) for 40 min at 37 8C
followed by 15 min at 85 8C. The sequencing
reaction was carried out using the Big Dye Terminator
Cycle Sequencing Ready Reaction Kit v.3Cases Controls
712 748
404 (56.7%) 434 (58%)
308 (43.2%) 314 (41.9%)
62 (29–90) 54 (29–91)
26.4 (20.6–34.3) 26.8 (21.1–34.6)
70 (16.4%) 38 (11.1%)
40 (9.5%) 34 (9.9%)
l.
e missing from 292 (41%) cases and 405 (54.1%) controls.
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(Applied Biosystems). The sequencing reaction was
performed using forward and reverse primers separately
with the following PCR conditions: 96 8C for 1 min, 27
cycles of 96 8C for 16 s, 54 8C for 5 s, and 60 8C for
4 min. The sequencing products were precipitated with
isopropanol, resuspended in 25 ml water, and loaded onto
an ABI PRISM 3130XL Genetic analyzer (Applied
Biosystems). The original data were analyzed using
Sequencing Analysis 5.2 software (Applied Biosystems)
for base calling. The obtained sequences were aligned
using DNAStar Lasergene 5.0 software (DNAStar Inc.,
Madison, WI, USA).Genotyping using Taq-Man assay
The polymorphisms C1127INSPstI in the INS gene,
Ile253Met in the IGFBPI gene, and Gly972Arg in the
IRS1 gene were investigated using the allelic discrimi-
nationmethod.TaqManprimers andprobeswereordered
as Assay-on-Demand (Assay Id: C__1223316_10,
C__1842782_10 and C__2384392_20 for the INS,
IGFBPI, and IRS1 genes respectively) from Applied
Biosystems. The reaction was performed in 5 ml using
225 nM each primer, 50 nM each probe, and 2.5 ml
TaqMan Universal 2! PCR Master Mix (Applied
Biosystems) per reaction. PCR was performed at 50 8C
for 2 min, 95 8C for 10 min followed by 40–55 cycles at
92 8C for 15 s, and 60 8C for 1 min. PCR was performed
in a GeneAmp PCR System 9700 thermocycler and the
number of cycles was dependent on the genotype
clustering. The samples were read and analyzed on the
ABI Prism 7900HT sequence detection system
using SDS 1.2 software (Applied Biosystems, Foster
City, CA, USA).Statistical analysis
The observed genotype frequencies in controls were
tested for Hardy–Weinberg equilibrium (HWE). The
best model to represent the relationship between
genotype and the risk of CRC was selected based on
likelihood ratio tests (LRTs). Odds ratios (ORs) with
95% confidence intervals (95% CIs) were estimated by
logistic regression. Statistical significance for a
different genotype distribution in cases versus controls
was determined by global c2 tests. With the present
sample size, we had a power of 90% to detect an OR of
0.5 for a dominant effect of a polymorphism with
MAFZ5%. To identify possible higher-order gene–
gene interactions among the insulin pathway genes, the
multifactor-dimensionality reduction method was
applied (Ritchie et al. 2001).736Results
A-603G polymorphism in INSR gene shows
protective effect
In the control population, the genotype distributions for
all the five studied SNPs were according to HWE. The
MAF and the genotype distribution for the INS
C1127INSPstI, IGFBPI Ile253Met, IRS1 Gly972Arg,
and IRS2 Gly1057Asp were concordant with the NCBI
database (http://www.ncbi.nlm.nih.gov/) and the pre-
viously published studies for Caucasians (Ho et al.
2003, Slattery et al. 2004, Li et al. 2005, Neuhausen
et al. 2005, Wagner et al. 2007). No study about the
INSR SNP has been published. Table 2 shows the
genotype distributions of the SNPs studied in the INS,
INSR, IGFBPI, IRS1, and IRS2 genes in our study
population and their effect on the risk of CRC. The
only significant association was found between the
INSR (A-603G) genotypes and the risk of CRC (global
c2Z6.15, PZ0.046). For this locus, the observed
genotype distributions were represented better by a
dominant model than by a three-genotype model
(c2 LRTZ0.092, PZ0.762). Under dominance, the
estimated OR for GG/AG versus AA genotype was
0.71 (95% CIZ0.54–0.93).Gene–gene interaction
We investigated the mutual effect of the insulin
signaling-related genes because insulin regulates the
bioavailabilityofIGFBPIaswellas itbindstoits receptor
to start the downstream signaling pathway through IRS1
and IRS2. Thus, the combined effect of the genotypes in
these genesmay be amore important risk factor forCRC
than the individual genotypes. In order to investigate the
possible gene–gene interactions, INSR genotypes based
on the dominant model were further stratified. The
stratification of INSR genotypes according to the two
IRS1 genotypes (AA/GA and GG) was adequate from a
statistical point of view (c2LRTZ7.649,PZ0.022) and
it constituted thebestmodel, thus indicatinga significant
interaction between INSR and IRS1 genotypes on the
risk of CRC. Under this model, the global c2 for the
genotype effect showed a significance effect (c2Z9.88
(PZ0.02)) and the estimatedORfor carriers of the INSR
GG/AG and the IRS1 AA/GA genotypes was 0.28
(95% CIZ0.11–0.70) (Table 3). We used the multi-
factor-dimensionality reduction method in order to
identify other gene–gene interactions between the
insulin pathway genes, but no associations
were detected.
Information on BMI and treatment for diabetes was
available for 59.0% of the cases and 45.9% ofwww.endocrinology-journals.org
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Table 2 Genotype distributions of the polymorphisms in the INS, INSR, insulin-like growth factor-binding protein I (IGFBPI), insulin
receptor substrate 1 (IRS1), and IRS2 genes among the colorectal cancer (CRC) cases and controls




value OR (95% CI)a
INS
(C1127INSPstI)
rs3842752 CC 403 (60.4) 440 (61.4) 1.95 0.378 1
CT 237 (35.7) 241 (33.6) 1.09 (0.86–1.38)
TT 24 (3.6) 36 (5.0) 0.74 (0.42–1.29)
INSR (A-603G) rs1864010 AA 504 (80.6) 525 (74.3) 6.15 0.046 1
AG 108 (17.3) 162 (22.9) 0.70 (0.53–0.93)
GG 13 (2.1) 20 (2.8) 0.78 (0.37–1.62)
AGCGGb 121 (19.4)b 182 (25.7)b 6.09b 0.014b 0.71 (0.54–0.93)b
IGFBPI (Ile253Met) rs4619 AA 305 (47.0) 314 (44.5) 1.07 0.585 1
AG 269 (41.5) 310 (44.0) 0.90 (0.71–1.15)
GG 75 (11.6) 81 (11.5) 1.06 (0.74–1.54)
IRS1 (Gly972Arg) rs1801278 GG 590 (88.7) 627 (86.4) 1.13 0.568 1
GA 74 (11.1) 96 (13.2) 0.85 (0.61–1.19)
AA 1 (0.2) 3 (0.4) 0.56 (0.06–5.44)
IRS2 (Gly1057Asp) rs1805097 GG 211 (37.1) 268 (39.2) 1.60 0.451 1
GA 277 (48.7) 309 (45.2) 1.15 (0.89–1.48)
AA 81 (14.2) 106 (15.5) 0.97 (0.68–1.38)
Odds ratios (ORs) and 95% confidence interval (CI) limits were calculated.
aAdjusted for age and sex.
bRepresents the dominant genotype model. The number of cases and controls varies between SNPs because of a few missing
genotype data.
Endocrine-Related Cancer (2007) 14 733–740the controls. The BMI or the proportion of cases treated
for diabetes did not depend on the INSR or the IRS2
genotypes (data not shown). Only 70 cases (16.7%) and
38 controls (11.1%) were reported to have diabetes. In
this small subgroup of subjects, the association
between development of CRC and diabetes treatment
was not significant (PZ0.36).Discussion
Studies linking insulin resistance, obesity, and CRC
(Calle & Kaaks 2004, Biddinger & Kahn 2006) suggest
that the insulin pathway may play an important role in
the etiology of CRC (Giovannucci 2001). In order to
investigate the influence of genetic variation in the
insulin pathway related genes on the risk of CRC, weTable 3 Joint effect of the polymorphisms in the INSR and
insulin receptor substrate 1 (IRS1) genes in the Czech
colorectal cancer (CRC) cases and controls
Genotype
INSR IRS1 Cases Controls OR (95% CI)a
AA GG 432 699 1.00
AA AA/GA 65 71 1.00 (0.69–1.45)
GG/AG GG 113 155 0.78 (0.58–1.04)
GG/AG AA/GA 6 24 0.28 (0.11–0.70)
aAdjusted for age and sex.
www.endocrinology-journals.orggenotyped SNPs in the INS, INSR, IGFBPI, IRS1, and
IRS2 genes in a cohort of cases and controls from the
Czech Republic.
This is the first study to evaluate the effect of
variants in several genes along the INS pathway on the
risk of CRC. Previously, INS, INSR, IRS1, and IRS2
SNPs have been studied with regard to advanced
colorectal adenoma, a cancer precursor (Gunter et al.
2007) and only IRS1 and IRS2 SNPs with regard to the
risk of CRC (Slattery et al. 2004). In our study, the
variant allele carriers of the INSR gene were at a
significantly decreased risk of CRC. Further stratifica-
tion of the INSR genotypes showed a gene–gene
interaction between the INSR and the IRS1 genes.
Carriers with the variant alleles of the two genes had
even lower risk of CRC than the carriers of the
protective INSR allele. However, although the number
of carriers of the individual genotypes among controls
was quite high (25.7% for INSR and 13.6% for IRS1
respectively), only 6 cases and 24 controls carried the
variant alleles of the two genes. The studied SNPs in
the INS, IGFBPI, and IRS2 genes were not statistically
significantly associated with the risk of CRC.
In the INSR gene, the region 1800 bp upstream of the
translation start site contains many regulatory elements
which have been reported to be required for proper
expression of INSR and appropriate insulin signaling737
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and action (Araki et al. 1991, Foti et al. 2003). The
removal or mutational inactivation of the four Sp1
elements present between K618 and K593 bp has
been shown to reduce promoter activity of the gene by
about 90% (Yoshizato et al. 2001, Foti et al. 2003). In
the present study, we investigated the A-603G
polymorphism which lies within the consensus
sequence for Sp1 binding and has been shown to affect
Sp1 binding (Kadonaga et al. 1986). However, a later
study has not observed any effect of this SNP on the
promoter activity (Haruta et al. 1995). Interestingly, in
our study the G allele carrier status was associated with
a significantly decreased risk for CRC. In consistence
with our results, the A allele has been suggested to be a
risk factor for insulin resistance (Kadowaki et al.
1990). Recently, Gunter et al. (2007) used haplotype-
tagging SNP approach to comprehensively investigate
the association of genetic variation in the INSR gene
with the risk of advanced colorectal adenoma.
Although the studied SNPs did not seem to have any
effect on the risk of adenoma, the authors found
evidence of the effect modification by BMI on the
association of INSR gene variants and the risk of
colorectal adenoma. However, they could not find any
individual SNP that would have explained the
significance of the interaction. There are at least two
possible explanations to the different results obtained
by Gunter et al. and by us. The study by Gunter et al.
did not include any SNPs in the promoter, where the
A-603G SNP studied by us is located, and no data of
LD between the SNPs in the promoter and the gene
region are available. Another difference between these
two studies is that the cases in our study were
diagnosed with CRC, the cases in the study by Gunter
et al. with advanced colorectal adenoma, a cancer
precursor.
The IRS1 Gly972Arg polymorphism lies between
two tyrosine residues, which upon phosphorylation are
involved in a further interaction with the downstream
signaling molecules (Wagner et al. 2004). The Arg
variant has been shown to have decreased binding to
the p85 regulatory subunit of PI-3 kinase, resulting in
impaired insulin-stimulated signaling (Almind et al.
1996). The Gly972Arg SNP has been intensively
studied for type 1 and 2 diabetes, polycystic ovary
syndrome, obesity, and metabolic disorders with
inconsistent results (Wagner et al. 2007). The Arg
allele has been associated with an increased risk of
CRC but not with breast cancer (Slattery et al. 2004,
Wagner et al. 2004). In one study, the risk of prostate
cancer has been shown to be increased among Arg
allele carriers (Neuhausen et al. 2005), while another
study found no association (Li et al. 2005). In our738study, the Gly972Arg SNP was not statistically
significantly associated with the risk of CRC.
However, the risk of the carriers of the protective
INSR allele was even more decreased in individuals
carrying the IRS1 Arg allele. This effect can be
explained by the assumed impaired insulin signaling
due to the variant alleles of these two genes (Kadowaki
et al. 1990, Almind et al. 1996).
The IRS2 Gly1057Asp polymorphism also lies close
to two putative phosphorylation tyrosine sites;
however, no effect of its binding ability to the p85
subunit of PI-3 kinase has been observed (Wagner
et al. 2004). Similar to IRS1, several studies with
inconsistent effects of the IRS2 SNP have been
observed in insulin resistance-related diseases (Wagner
et al. 2007). No association has been detected in
studies of breast and prostate cancer (Wagner et al.
2004, Neuhausen et al. 2005). In CRC, heterozygotes,
but not the homozygotes, for the Asp allele, have been
shown to be at reduced risk (Slattery et al. 2004). In our
study, the IRS2 Gly1057Asp showed no association
with the risk of CRC.
The C1127INSPstI is located in the 30-untranslated
region (UTR) of the INS gene. The 30-UTR plays a
prominent role in mRNA stability and may thus regulate
insulin production (Ho et al. 2003). It is also in LDwith a
VNTR locus, which has consistently shown linkage with
diabetes (Bennett &Todd 1996). Our data did not show a
significant association between the SNP and the risk of
CRC. Earlier, Ho et al. (2003) and Claeys et al. (2005)
have suggested an association between the
C1127INSPst1 CC genotype and an increased risk of
prostate cancer. However, two other studies have not
found any effect of the INS SNP on the risk of prostate
cancer (Li et al. 2005, Neuhausen et al. 2005).
In the recent study by Gunter et al. (2007) the effect
of several SNPs in the INS, IRS1, and IRS2 genes on the
risk of advanced colorectal adenoma was investigated.
They selected the SNPs in each gene based mainly on
their putative effect on hyperinsulinemia and insulin
resistance, but they did not observe any association
with adenoma. The SNPs which we studied were not
included in their study in spite of their functional
effects and reported linkage with different insulin-
related diseases as discussed above.
High levels of IGFBPI have been shown to
significantly decrease the risk of CRC (Kaaks et al.
2000). In a study by Stephens et al. (2005) two tightly
linked SNPs were associated with a reduced prevalence
of diabetic nephropathy with the Ile253Met determin-
ing the strongest protection. This SNP would most
likely affect some aspects of post-translational function
of the protein as it is located close to the RGD motif inwww.endocrinology-journals.org
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the C terminus and may affect the interaction with IGFI
(Stephens et al. 2005). In our study, we did not observe
any association of the Ile253Met polymorphism with
the risk of CRC. This result is in concordance with a
recent study by Cheng et al. (2006) in which they
conducted a haplotype-based study and found no
association with the risk of prostate and breast cancer.
Tight LD has been observed in the regions of the INS
and the IGFBPI genes. In such a region, assaying for
one marker would generally provide genotype infor-
mation of all the others (Bennett & Todd 1996,
Stephens et al. 2005, Cheng et al. 2006). To observe a
dominant effect, our study had a 90% power to detect
an OR of 1.4. However, the power to detect a recessive
effect was much lower (!60%). Thus, we can only
exclude a major effect of the INS and IGFBPI SNPs on
the risk of CRC.
The limitations of our study include the difference in
the age between the cases and the controls. However,
no age- or gender-specific differences in the genotype
distributions were observed. Another limitation was
the limited availability of the data about BMI and
diabetes, 59.0% among the cases and only 45.9%
among the controls. Additionally, the BMI data of the
cases were retrieved at the time of diagnosis and
the data of diabetes were self-reported, restricting the
usefulness of the information.
In conclusion, our results suggest a reduced risk of
CRC for carriers of the INSR-603G allele. The
protective effect was even stronger among carriers of
both the INSR-603G and the IRS1 972Arg alleles.
These results need to be confirmed in other indepen-
dent sample sets. Because of a relationship between
insulin-related diseases and CRC, SNPs in the insulin
pathway genes may have a more prominent effect on
the risk of CRC in diabetic and obese individuals,
which warrants further studies.Acknowledgements
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